NEWS - Jan 26, 2016 Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern Read more
NEWS - Jan 11, 2016 Relmada Therapeutics Selected to Present at 2016 Biotech Showcase™ in San Francisco Read more
NEWS - Jan 4, 2016 Relmada Therapeutics Successfully Completes Multiple Ascending Dose Study of d-Methadone for Neuropathic Pain Read more
NEWS - Dec 30, 2015 Relmada Therapeutics Announces Results of Annual Meeting of Stockholders Read more
NEWS - Dec 28, 2015 Relmada Therapeutics Recommends Stockholders Vote "FOR" Relmada's Director Nominees on the WHITE Proxy Card Today Read more
NEWS - Dec 23, 2015 U.S. Federal Court Grants Preliminary Injunction Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern Read more
NEWS - Dec 21, 2015 Relmada Sends Letter To Stockholders Highlighting Significant Progress In Value Creation Strategy Overseen By Board And Management Team Read more
NEWS - Dec 15, 2015 Leading Independent Proxy Advisory Firm Glass Lewis Recommends Relmada Stockholders Vote the WHITE Proxy Card "FOR" Relmada's Director Nominees: Shreeram Agharkar and Maged Shenouda Read more
NEWS - Dec 14, 2015 Pharmaceutical Industry Leader James Dolan Joins Relmada Therapeutics Advisory Team Read more
NEWS - Dec 11, 2015 U.S. Federal Court Issues Temporary Restraining Order Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern Read more
